The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion. The company expects the full ...